EXELON®
Rivastigmine as the hydrogen tartrate

NAME OF THE MEDICINE
Rivastigmine as the hydrogen tartrate

Structural Formula:

![Chemical structure](image)

Chemical name: (S)-N-ethyl-N-methyl-3-[1-(dimethylamino)ethyl]-phenyl carbamate hydrogen-(2R,3R)-tartrate

Molecular formula: C₁₄H₂₂N₂O₂ . C₄H₆O₆

Molecular weight: 400.4

CAS number: 129101 - 54 - 8

DESCRIPTION

Active ingredient

Rivastigmine hydrogen tartrate is a white to off-white, fine crystalline powder that is very soluble in water, soluble in ethanol and acetonitrile, slightly soluble in n-octanol, and very slightly soluble in ethyl acetate.

Excipients

Exelon 1.5mg, 3mg and 6mg capsules: hypromellose, magnesium stearate, cellulose-microcrystalline, silica-colloidal anhydrous, gelatin, iron oxide red, iron oxide yellow, titanium dioxide, and TekPrint SW-1102 Red ink (ARTG PI No. 107015).

Exelon 4.5mg capsules: hypromellose, magnesium stearate, cellulose-microcrystalline, silica-colloidal anhydrous, gelatin, iron oxide red, iron oxide yellow, titanium dioxide, and Opacode monogramming ink S-1-18086 White (ARTG PI No. 107579).

Exelon Oral solution: sodium benzoate, citric acid, sodium citrate, quinoline yellow and purified water.
PHARMACOLOGY

Pharmacodynamics

Pathological changes in Alzheimer’s Disease involve cholinergic neuronal pathways that project from the basal forebrain to the cerebral cortex and hippocampus. These pathways are known to be involved in attention, learning, memory and other cognitive processes. Rivastigmine, a brain-selective, pseudo-reversible inhibitor of the enzymes acetyl- and butyryl-cholinesterase, is thought to facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine released by functionally intact cholinergic neurons. Data from animal studies indicate that rivastigmine selectively increases the availability of acetylcholine in the cortex and hippocampus. Thus, Exelon may have an ameliorative effect on cholinergic-mediated cognitive deficits associated with Alzheimer’s Disease. In addition, there is some evidence that cholinesterase inhibition could slow the formation of amyloidogenic β-amyloid-precursor protein (APP) fragments, and thus of amyloid plaques, which are one of the main pathological features of Alzheimer’s Disease.

Rivastigmine interacts with its target enzyme by forming a covalently bound complex that temporarily inactivates the enzyme. In healthy young men, an oral 3.0 mg dose decreases acetylcholinesterase (AChE) activity in CSF by approximately 40% within the first 1.5 hours after administration. Activity of the enzyme returns to baseline levels about 9 hours after the maximum inhibitory effect has been achieved. Butyrylcholinesterase (BuChE) activity in CSF was transiently inhibited and was no longer different from baseline after 3.6 hours in healthy young volunteers. In patients with Alzheimer’s Disease, inhibition of acetylcholinesterase in CSF by rivastigmine is dose-dependent up to 6 mg given twice daily, the highest dose tested. Inhibition of BuChE activity in the CSF of 18 patients with Alzheimer’s Disease was similar to that of AChE, with a change from baseline of more than 60% after 6 mg rivastigmine twice daily. The effect of rivastigmine on AChE and BuChE activity in CSF (a reduction from baseline of 33% and 45%, respectively) was sustained in 11 patients after administration of rivastigmine at a mean dose of 8.6 mg/day for 12 months. Statistically significant correlations were found between the degree of inhibition by rivastigmine of AChE and BuChE in the CSF and changes on a compound measure of cognitive performance, the Computerised Neuropsychological Test Battery (CNTB), in 18 patients with Alzheimer’s Disease treated with daily doses of rivastigmine of 2, 4, 6, 8, 10 or 12 mg (3 subjects per dose) for a duration of at least 3 consecutive days. However, only BuChE inhibition in CSF was significantly and consistently correlated with improvements in speed-, attention- and memory-related subtests of the CNTB. The clinical significance of the inhibitory effect of rivastigmine on BuChE in patients with Alzheimer’s Disease is unknown.

Pharmacokinetics

Rivastigmine is well absorbed with absolute bioavailability of about 40% (3 mg dose). It shows linear pharmacokinetics up to 3 mg twice daily but is non-linear at higher doses. Doubling the dose from 3 to 6 mg twice daily results in a 3-fold increase in AUC. The elimination half-life is about 1.5 hours, with most elimination as metabolites via the urine.

Absorption:

Rivastigmine is rapidly and completely absorbed. Peak plasma concentrations are reached in approximately 1 hour. Due to the drug’s interaction with its target enzyme, over the dose range of 1.5 mg to 6 mg twice daily, bioavailability (AUC) approximately tripled with doubling of the dose. Absolute bioavailability after a 3 mg dose is about 36%. Administration of rivastigmine
capsules with food delays absorption ($t_{\text{max}}$) by 90 min and lowers $C_{\text{max}}$ and increases AUC by approximately 30%. Administration of rivastigmine oral solution with food delays absorption (median $t_{\text{max}}$) by 75 min, lowers $C_{\text{max}}$ by about 45% and increases AUC by approximately 15%.

**Distribution:**

Rivastigmine is weakly bound to plasma proteins (approximately 40%). The apparent volume of distribution of rivastigmine is in the range of 1.8-2.7 L/kg. Rivastigmine penetrates the blood brain barrier, reaching CSF peak concentrations in 1.4-2.6 hours. Mean $AUC_{1-12h}$ ratio of CSF/plasma averaged 40± 0.5% following 1-6 mg twice daily doses. Rivastigmine distributes equally between blood and plasma with a blood-to-plasma partition ratio of 0.9 at concentrations ranging from 1-400 ng/mL.

**Metabolism:**

Rivastigmine is rapidly and extensively metabolised (half-life in plasma approximately 1 hour), primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite. *In vitro*, this metabolite shows minimal inhibition of acetylcholinesterase (<10%). Based on evidence from *in vitro* and animal studies, the major cytochrome P450 isoenzymes are minimally involved in rivastigmine metabolism. Consistent with these observations is the finding that no drug interactions related to cytochrome P450 have been observed in humans (see “PRECAUTIONS - Interactions with Other Drugs”).

**Excretion:**

Unchanged rivastigmine is not found in the urine. Renal excretion of the metabolites is the major route of elimination. Following administration of $^{14}$C-rivastigmine, renal elimination was rapid and essentially complete (> 90%) within 24 hours. Less than 1% of the administered dose is excreted in the faeces. There is no accumulation of rivastigmine or the decarbamylated metabolite in patients with Alzheimer’s Disease. Mean oral clearance of rivastigmine is 1.8 ± 0.6 L/min after 6 mg twice daily.

**Pharmacokinetics in the elderly:**

While the bioavailability of rivastigmine was greater in elderly volunteers than in young healthy volunteers, studies in patients with Alzheimer’s Disease aged between 50 and 92 years showed no change in bioavailability with age.

**Pharmacokinetics in renal impairment:**

Following a single 3 mg dose, mean oral clearance of rivastigmine is 64% lower in moderately impaired renal patients (n=8, GFR 10-50 mL/min) than in healthy subjects (n=10, GFR 60 mL/min); $CL/F=1.7$ L/min (cv=45%) and 4.8 L/min (cv=80%), respectively. In severely impaired renal patients (n=8, GFR <10mL/min), mean oral clearance of rivastigmine is 43% higher than in healthy subjects (n=10, GFR 60 mL/min); $CL/F = 6.9$ L/min and 4.8 L/min, respectively. For unexplained reasons, the severely impaired renal patients had a higher clearance of rivastigmine than moderately impaired patients. However, dosage adjustment may not be necessary in renally impaired patients as the dose of the drug is individually titrated to tolerability. (see "DOSAGE AND ADMINISTRATION - Use in patients with renal or hepatic impairment").
Pharmacokinetics in hepatic impairment:

Following a single 3 mg dose, mean oral clearance of rivastigmine was 60% lower in hepatically impaired patients (n=10, biopsy proven) than in healthy subjects (n=10). After multiple 6 mg twice daily oral dosing, the mean clearance of rivastigmine was 65% lower in mild (n=7, Child-Pugh score 5-6) and moderate (n=3, Child-Pugh score 7-9) hepatically impaired patients (biopsy proven, liver cirrhosis) than in healthy subjects (n=10). Dosage adjustment is not necessary in hepatically impaired patients as the dose of drug is individually titrated to tolerability. (see "DOSAGE AND ADMINISTRATION - Use in patients with renal or hepatic impairment").

Age:

Following a single 2.5 mg oral dose to elderly volunteers (>60 years of age, n=24) and younger volunteers (n=24), mean oral clearance of rivastigmine was 30% lower in elderly (7 L/min) than in younger subjects (10 L/min).

Gender and race:

No specific pharmacokinetic study was conducted to investigate the effect of gender and race on the disposition of Exelon, but a population pharmacokinetic analysis indicates that gender (n=277 males and 348 females) and race (n=575 white, 34 black, 4 Asian and 12 other) did not affect the clearance of Exelon.

Nicotine use:

Population pharmacokinetic analysis showed that nicotine use increases the oral clearance of rivastigmine by 23% (n=75 smokers and 549 nonsmokers).

CLINICAL TRIALS

The effectiveness of Exelon as a treatment for Alzheimer’s Disease was demonstrated by the results of two randomised, double-blind, placebo-controlled clinical investigations in patients with Alzheimer’s Disease (diagnosed by NINCDS-ADRDA and DSM-IV criteria, Mini-Mental State Examination (MMSE) ≥10 and ≤ 26, and the Global Deterioration Scale). Proof of efficacy was further reinforced through a pooled analysis of the two pivotal studies and a third supportive randomised, double-blind, placebo controlled trial. The mean age of patients participating in the Exelon trials was 73 years with a range of 41 to 95. Approximately 59% of patients were women and 41% were men. The racial distribution was Caucasian 87%, Black 4% and other races 9%.

Study Outcome Measures: In each study, the effectiveness of Exelon was determined from a performance-based measure of cognition, a clinician's global assessment of change and a standard instrument evaluating activities of daily living through caregiver-related evaluation. The results of these two studies indicate that a statistically significantly higher proportion of patients on Exelon experienced clinical benefit.

The ability of Exelon to improve cognitive performance was assessed with the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog), a multi-item instrument that has been extensively validated in longitudinal cohorts of Alzheimer’s Disease patients.
The ADAS-cog examines selected aspects of cognitive performance including elements of memory, orientation, attention, reasoning, language and praxis. The ADAS-cog scoring range is from 0 to 70, with higher scores indicating greater cognitive impairment. Elderly normal adults may score as low as 0 or 1, but it is not unusual for non-demented adults to score slightly higher.

The patients recruited as participants in each study had mean scores on the Alzheimer’s Disease Assessment Scale (ADAS-cog) of approximately 23 units, with a range from 1 to 61. Experience gained in longitudinal studies of ambulatory patients with mild to moderate Alzheimer’s Disease suggests that they gain 6 to 12 units a year on the ADAS-cog. However, lesser degrees of change are seen in patients with very mild or very advanced disease because the ADAS-cog is not uniformly sensitive to change over the course of the disease. The annualised rate of decline in the placebo patients participating in Exelon trials was approximately 3 to 8 units per year.

The ability of Exelon to produce an overall clinical effect was assessed using a Clinician’s Interview Based Impression of Change that required the use of caregiver information, the CIBIC-Plus. The CIBIC-Plus is not a single instrument and is not a standardised instrument like the ADAS-cog. Clinical trials for investigational drugs have used a variety of CIBIC formats, each different in terms of depth and structure. As such, results from a CIBIC-Plus reflect clinical experience from the trial or trials in which it was used and cannot be compared directly with the results of CIBIC-Plus evaluations from other clinical trials. The CIBIC-Plus used in Exelon trials was a semi-structured instrument based on a comprehensive evaluation at baseline and subsequent time-points of three domains: patient cognition, behavior and functioning. It represents the assessment of a skilled clinician, using validated scales based on his/her observation, at interviews conducted separately with the patient and the caregiver familiar with the behavior of the patient over the interval rated. The CIBIC-Plus is scored as a seven point categorical rating, ranging from a score of 1 indicating “markedly improved”, to a score of 4 indicating “no change”, to a score of 7 indicating “marked worsening”. The CIBIC-Plus has not been systematically compared directly to assessments not using information from caregivers (CIBIC) or other global methods.

The ability of Exelon to improve activities of daily living (ADL) was assessed using the Progressive Deterioration Scale (PDS). The PDS examines selected aspects of activities of daily living including elements of use of household instruments, leisure activities, household tasks, self-care and behavior in social settings. This is a 29-item scale that is a caregiver-rated evaluation of the patient’s activities of daily living. The primary measure of clinical improvement was defined as a 10% or higher improvement on the PDS.

**U.S. Twenty-Six Week Study**

In a study of 26 weeks duration, 699 patients were randomised to either a dose range of 1-4 mg or 6-12 mg of Exelon per day or placebo in divided doses. The 26 week study was divided into a 12 week forced titration phase and a 14 week maintenance phase. The study was designed to compare 1-4 and 6-12 mg/day flexible doses of Exelon. The patients in the active treatment arms of the study were maintained at their highest tolerated dose within the respective range.

The mean age of the patients was 75 years (range: 45 to 89). At baseline the mean MMSE score was 19.7 and the mean Global Deterioration Scale score was 4.0, with greater than 30% of the patients being rated as moderately severe in their disease.
Effects on the ADAS-cog: Figure 1 illustrates the time course for the change from baseline in ADAS-cog scores for all three dose groups over the 26 weeks of the study. At the first measurement of efficacy (Week 12), the mean differences between the 1-4 mg group with placebo and the 6-12 mg group with placebo were 0.87 units and 3.32 units, respectively. The difference between the 6-12 mg group and placebo was significant, indicating an onset of efficacy at or before 12 weeks of treatment. At 26 weeks of treatment, the mean differences in the ADAS-cog change scores for the Exelon treated patients compared to the patients on placebo were 1.88 and 4.94 units for the 1-4 mg and 6-12 mg treatments, respectively. These differences were statistically significant. The treatment effect size is slightly greater for the 6-12 mg treatment. This difference is also statistically significant.

Figure 1:  
Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment

![Time Course of the Change from Baseline in ADAS-cog Score for Patients Completing Evaluations during Treatment Period](image)

Effects on the CIBIC-Plus: At 26 weeks of treatment, the mean differences in the CIBIC-Plus scores for the Exelon treated patients compared to the patients on placebo were 0.32 and 0.35 units for the 1-4 mg and the 6-12 mg groups, respectively. These differences were statistically significant and the difference between the two active treatments was also statistically significant.

Effects on the PDS: The PDS, which examines selected aspects of activities of daily living including elements of use of household instruments, leisure activities, household tasks, self-care and behavior in social settings, demonstrated that, while the placebo group declined an average of 4.9 units, the Exelon 6-12 mg group deteriorated minimally (1 unit), a difference which was statistically significant (intent-to-treat analysis). Figure 2 illustrates the time course of the change from baseline in PDS scores for all three dose groups over the 26 weeks of the study.
Figure 2: Time Course of the Change from Baseline to Last Measurement Taken in PDS Score

Global Twenty Six Week Study

An additional 26-week multi-national, multi-center trial using three different languages was performed in six different countries using the same design as the US 26-week study. A total of 725 patients were randomised into the three treatment arms: 243 patients, 6-12 mg/day Exelon; 243 patients, 1-4 mg/day Exelon; and 239 patients, placebo. Overall, 581 (80%) patients completed the study, while 144 (20%) discontinued. A significantly higher proportion of patients in the 6-12 mg/day group (33%) than in the placebo group (13%) stopped treatment early. There was no difference between the 1-4 mg/day (14%) and placebo groups in the number of discontinuations.

Efficacy was demonstrated in the three key domains (i.e. cognition, global functioning and ADL) using the same outcome measures as the US 26-Week study. Significant efficacy was shown in all major population analyses (ITT, LOCF, and OC) for the 6-12 mg group, both in the analysis of mean change from baseline as well as of patients showing a clinically meaningful response. The results indicated that the 6-12 mg/day dose range of Exelon was statistically significantly superior to placebo for measures assessing cognition, global functioning, activities of daily living (mean change and “responders”) and for severity of the disease, while the low dose group had significantly higher number of patients considered CIBIC-Plus responders compared to placebo. An effect on cognitive function was seen as early as Week 12 and this effect was maintained until Week 26.

Symptom and Subtest Analyses: Pooled analyses performed to detect those subtests and symptoms of the ADAS-Cog and CIBIC-Plus, respectively, which improved in patients treated with Exelon indicated that most ADAS-Cog subtests (ideational praxis, orientation, test instructions, word recall, language ability and word recognition) were significantly improved at week 26 with Exelon 6-12 mg. For the CIBIC-Plus, significant improvement was seen for cognition (concentration and recent memory), functioning (consecutive staging), and behavior (purposeless activity and some delusions).
**INDICATIONS**

Exelon is indicated for the treatment of patients with mild to moderately severe dementia of the Alzheimer’s type.

**CONTRAINDICATIONS**

The use of Exelon is contraindicated in patients with:

- known hypersensitivity to rivastigmine, to the excipients of the formulation, or to other carbamate derivatives.

- previous history of application site reactions suggestive of allergic contact dermatitis with rivastigmine transdermal patch (see “PRECAUTIONS – Skin reactions”).

- severe liver impairment since it has not been studied in this population.

**PRECAUTIONS**

Treatment should always be started at a dose of 1.5 mg twice daily and titrated to the patient’s maintenance dose. If treatment is interrupted for longer than several days, treatment should be re-initiated with the lowest daily dose to reduce the possibility of adverse reactions (e.g. severe vomiting)[see "DOSAGE and ADMINISTRATION”].

**Gastrointestinal adverse reactions:**

Significant gastrointestinal disorders such as nausea, vomiting, diarrhoea, anorexia and weight loss may occur when initiating treatment and/or increasing the dose. They may respond to a dose reduction. In other cases, Exelon has been discontinued.

Patients who show signs or symptoms of dehydration resulting from prolonged vomiting or diarrhoea can be managed with iv fluids and dose reduction or discontinuation if recognized and treated promptly. Dehydration can be associated with serious outcomes (see ADVERSE EFFECTS).

**Nausea and vomiting:** In the controlled clinical trials, 47% of the patients treated with an Exelon dose in the therapeutic range of 6 to 12 mg/day (n=1189) developed nausea (compared with 12% for placebo). A total of 31% of Exelon-treated patients developed at least one episode of vomiting (compared with 6% for placebo). The rate of vomiting was higher during the titration phase (24% vs 3% for placebo) than in the maintenance phase (14% vs 3% for placebo). The rates were higher in women than men. Five percent of patients discontinued for vomiting compared to less than 1% of patients on placebo. Vomiting was severe in 2% of Exelon-treated patients and was rated as mild or moderate each in 14% of patients. The rate of nausea was higher during the titration phase (43% vs 9% for placebo) than in the maintenance phase (17% vs 4% for placebo).

**Anorexia:** Patients with Alzheimer’s disease may lose weight whilst taking cholinesterase inhibitors, including rivastigmine.
In the controlled clinical trials, of the patients treated with an Exelon dose of 6 to 12 mg/day, 17% developed anorexia compared to 3% of the placebo patients. Neither the time course or the severity of the anorexia is known.

**Weight loss:** The patient’s weight should be monitored during therapy with Exelon.

Patients with body weight below 50 kg may experience more adverse events and may be more likely to discontinue due to adverse events.

In the controlled trials, approximately 26% of women on high doses of Exelon (greater than 9 mg/day) had weight loss of equal to or greater than 7% of their baseline weight compared to 6% for placebo-treated patients. About 18% of the males in the high dose group experienced a similar degree of weight loss compared to 4% of placebo-treated patients. It is not clear how much of the weight loss was associated with anorexia, nausea, vomiting and the diarrhoea associated with the drug.

**Peptic ulcers/gastrointestinal bleeding:** Because of their pharmacological action, cholinesterase inhibitors may be expected to increase gastric acid secretion due to increased cholinergic activity. Therefore, patients should be monitored closely for symptoms of active or occult gastrointestinal bleeding, especially those at increased risk for developing ulcers, e.g. those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of Exelon have shown no significant increase relative to placebo in the incidence of either peptic ulcer disease or gastrointestinal bleeding.

**Anaesthesia:**

Rivastigmine, as a cholinesterase inhibitor, is likely to exaggerate succinylcholine-type relaxation during anaesthesia.

**Cardiovascular conditions:**

Drugs that increase cholinergic activity may have vagotonic effects on heart rate (e.g. bradycardia). The potential for this action may be particularly important to patients with "sick sinus syndrome" or other supraventricular cardiac conduction conditions. In clinical trials, Exelon was not associated with any increased incidence of cardiovascular adverse events, heart rate or blood pressure changes, or ECG abnormalities. Syncopal episodes have been reported in 3% of patients receiving 6-12 mg/day of Exelon, compared to 2% of placebo patients.

**Pulmonary conditions:**

As with other cholinomimetics, Exelon should be used with caution in patients with a history of asthma or obstructive pulmonary disease. There is evidence from animal studies that rivastigmine may potentiate bronchoconstriction.

**Other conditions:**

Cholinomimetics may exacerbate urinary obstruction and seizures. However, seizure activity also may be a manifestation of Alzheimer's Disease. Although this has not been observed with Exelon, caution is recommended in such cases.
Skin reactions

In patients who develop application site reactions suggestive of allergic contact dermatitis to Exelon Patch and who still require rivastigmine, treatment should be switched to oral rivastigmine only after negative allergy testing and under close medical supervision. It is possible that some patients sensitised to rivastigmine by exposure to rivastigmine patch may not be able to take rivastigmine in any form.

Allergic contact dermatitis should be suspected if application site reactions spread beyond the patch size, if there is evidence of a more intense local reaction (e.g. increasing erythema, edema, papules, vesicles) and if symptoms do not significantly improve within 48 hours after patch removal. In these cases, treatment should be discontinued (see “CONTRAINDICATIONS”).

There have been isolated post-marketing reports of patients experiencing disseminated skin hypersensitivity reactions when administered rivastigmine irrespective of the route of administration (oral, transdermal). In these cases, treatment should be discontinued (see “CONTRAINDICATIONS”). Patients and caregivers should be instructed accordingly.

Special excipients

One of the excipients in Exelon Oral solution is sodium benzoate. Benzoic acid is a mild irritant to the skin, eyes and mucous membrane.

Information for patients and caregivers:

Caregivers should be advised of the high incidence of nausea and vomiting associated with the use of the drug along with the possibility of anorexia and weight loss. Caregivers should be encouraged to monitor for these adverse events and inform the physician if they occur. It is critical to inform caregivers that, if therapy has been interrupted for more than several days, the next dose should not be administered until they have discussed this with the physician.

Effects on ability to drive or operate machinery:

Alzheimer’s disease dementia may cause gradual impairment of driving performance or compromise the ability to use machinery. Rivastigmine may induce dizziness and somnolence, mainly when initiating treatment or increasing the dose. Therefore, the ability of Alzheimer’s patients to continue driving or operating complex machines should be routinely evaluated by the treating physician.

Carcinogenicity, mutagenicity, impairment of fertility

Rivastigmine was not genotoxic in tests for gene mutation in vitro, for primary DNA damage in vivo, or for chromosomal damage in vivo. In tests for chromosomal damage in vitro, a small increase in the number of cells with chromosomal aberrations occurred at very high concentrations. However, there was no evidence of clastogenicity in the more relevant in vivo test. No evidence of carcinogenicity was found in studies conducted at doses of up to 1.1 mg base/kg/day in rats and up to 1.6 mg/kg/day in mice, although systemic exposures to rivastigmine were lower than in humans treated with the maximum recommended dose. These dose levels are approximately 0.9 times and 0.7 times the maximum recommended human daily dose of 12 mg per day on a mg/m² basis. Oral rivastigmine, at doses which achieved systemic drug exposures below the therapeutic value, had no effect on fertility in rats.
**Animal toxicity studies**

Animal toxicity tests of up to 52 weeks duration have been carried out in rat and dogs. No toxicity other than due to cholinergic stimulation was seen, but oral rivastigmine doses were limited by intolerance and systemic drug exposures were lower than the maximum therapeutic value, although those for the phenolic metabolite were generally higher.

**Use in patients with renal or hepatic impairment:**

No dose adjustment is necessary in patients with renal or hepatic impairment. However, due to increased exposure in renal impairment and mild to moderate hepatic impairment, dosing recommendations to titrate according to individual tolerability should be closely followed as patients with clinically significant renal or hepatic impairment might experience more adverse events (see "PHARMACOLOGY - Pharmacokinetics in renal impairment; Pharmacokinetics in hepatic impairment").

**Use in children:**

There is no experience with the use of Exelon in children. Exelon is not recommended for use in children.

**Use in Pregnancy (Pregnancy Category B2)**

Oral rivastigmine was not teratogenic in rats and rabbits at doses producing maternal toxicity, but systemic drug exposures in these studies were below the maximum therapeutic value. The safety of Exelon in human pregnancy has not been established.

**Use in Lactation**

Rivastigmine and its metabolites are excreted into the milk of lactating rabbits. It is not known whether excretion into human milk occurs, and patients taking Exelon should not breast-feed.

**INTERACTIONS WITH OTHER MEDICINES**

The patient group to be treated frequently takes additional medications. Therefore, physicians should carefully evaluate any concomitant drug administration in this patient group.

Rivastigmine is metabolised mainly through hydrolysis by esterases. Minimal metabolism occurs via the major cytochrome P450 isoenzymes. Based on *in vitro* studies, no pharmacokinetic interactions with drugs metabolised by the following isoenzyme systems are expected: CYP1A2, CYP2D6, CYP3A4/5, CYP2E1, CYP2C9, CYP2C8 or CYP2C19.

No pharmacokinetic interaction was observed between oral rivastigmine and digoxin, warfarin, diazepam or fluoxetine in single-dose studies in healthy volunteers. The elevation of prothrombin time induced by warfarin was not affected by administration of rivastigmine. No untoward effects on cardiac conduction were observed following concomitant administration of digoxin and rivastigmine.
Population pharmacokinetic analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antidiabetics (n=21), antihypertensives (n=72), beta-blockers (n=42), calcium channel blockers (n=75), antianginals (n=35), non-steroidal anti-inflammatory drugs (n=79), oestrogens (n=70), salicylate analgesics (n=177) and antihistamines (n=15). In addition, in clinical trials, no increased risk of clinically relevant untoward effects was observed in patients treated concomitantly with rivastigmine and these agents.

In view of its pharmacodynamic effects, rivastigmine should not be given concomitantly with other cholinomimetic drugs. Rivastigmine may also interfere with the activity of anticholinergic medications.

A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.

Population pharmacokinetic analysis showed that nicotine use increases the oral clearance of rivastigmine by 23% (n=75 smokers and 549 nonsmokers). (see "PHARMACOLOGY - Nicotine use").

**ADVERSE EFFECTS**

In general, adverse events are mild to moderate and usually resolve without therapeutic intervention. Incidence and severity of adverse events generally increase with higher doses.

**Adverse Events Reported in Controlled Trials**

Table 1 lists treatment emergent signs and symptoms that were reported in at least 2% of patients in placebo-controlled trials and for which the rate of occurrence was greater for patients treated with Exelon doses of 6-12 mg/day than for those treated with placebo. The prescriber should be aware that these figures cannot be used to predict the frequency of adverse events in the course of usual medical practice when patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with figures obtained from other clinical investigations involving different treatments, uses or investigators. An inspection of these frequencies, however, does provide the prescriber with one basis by which to estimate the relative contribution of drug and non-drug factors to the adverse event incidences in the population studied.

In general, adverse reactions were less frequent later in the course of treatment. No systematic effect of race or age could be determined on the incidence of adverse events in the controlled studies. Nausea, vomiting and weight loss were more frequent in women than men.
Table 1. Adverse Events Reported in Controlled Clinical Trials in at Least 2% of Patients Receiving Exelon (6-12 mg/day) and at a Higher Frequency than Placebo-treated Patients

<table>
<thead>
<tr>
<th>Body System/Adverse Event</th>
<th>Placebo (n=868)</th>
<th>Exelon (6-12 mg/day) (n=1189)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percent of Patients with any Adverse Event</td>
<td>79</td>
<td>92</td>
</tr>
<tr>
<td><strong>Autonomic Nervous System</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sweating increased</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Syncope</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td><strong>Body as a Whole</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accidental Trauma</td>
<td>9</td>
<td>10</td>
</tr>
<tr>
<td>Fatigue</td>
<td>5</td>
<td>9</td>
</tr>
<tr>
<td>Asthenia</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Malaise</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Influenza-like Symptoms</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Weight Decrease</td>
<td>&lt;1</td>
<td>3</td>
</tr>
<tr>
<td><strong>Cardiovascular Disorders, General</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td><strong>Central and Peripheral Nervous System</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>11</td>
<td>21</td>
</tr>
<tr>
<td>Headache</td>
<td>12</td>
<td>17</td>
</tr>
<tr>
<td>Somnolence</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Tremor</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td><strong>Gastrointestinal System</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>12</td>
<td>47</td>
</tr>
<tr>
<td>Vomiting</td>
<td>6</td>
<td>31</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>11</td>
<td>19</td>
</tr>
<tr>
<td>Anorexia</td>
<td>3</td>
<td>17</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>6</td>
<td>13</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>Constipation</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Flatulence</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Eructation</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td><strong>Psychiatric Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>Confusion</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>Depression</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Anxiety</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Hallucination</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Aggressive Reaction</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td><strong>Resistance Mechanism Disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary Tract Infection</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td><strong>Respiratory System</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhinitis</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

Other adverse events observed at a rate of 2% or more on Exelon 6-12 mg/day but at a greater or equal rate on placebo were chest pain, peripheral oedema, vertigo, back pain, arthralgia, pain, bone fracture, agitation, nervousness, delusion, paranoid reaction, upper respiratory tract...
infections, infection (general), coughing, pharyngitis, bronchitis, rash (general), urinary incontinence.

A few cases of angina pectoris, gastric and duodenal ulcers, gastrointestinal haemorrhage, bradycardia and seizures were observed.

As treatment with Exelon was not associated with alterations in any laboratory tests, including liver function tests or the ECG, no specific monitoring of these measures is required.

Post-marketing Surveillance

The following adverse reactions have been accumulated both from clinical studies with Exelon and since the introduction of Exelon into the market.

Adverse reactions are ranked under headings of frequency using the following convention: Very common (>10%); common (>1% to ≤10%); uncommon (>0.1% to ≤1%); rare (>0.01% to ≤0.1%); very rare (<0.01% including isolated reports).

Body as a whole:
Common: fatigue, asthenia, malaise, weight loss
Uncommon: fall

Cardiovascular:
Rare: angina pectoris, myocardial infarction
Very rare: hypertension, cardiac arrhythmia (e.g. bradycardia, atrio-ventricular block, atrial fibrillation and tachycardia)
Frequency not known: sick sinus syndrome

Central and peripheral nervous system:
Very common: dizziness
Common: headache, somnolence, tremor
Uncommon: syncope
Rare: seizures

Gastrointestinal:
Very common: nausea, vomiting, diarrhoea, loss of appetite
Common: abdominal pain, dyspepsia
Rare: gastric and duodenal ulcers
Very rare: gastrointestinal haemorrhage, pancreatitis, severe vomiting associated with oesophageal rupture

Hepatobiliary disorders:
Uncommon: abnormal hepatic function tests
Frequency not known: hepatitis

Infections:
Very rare: urinary tract infection
Metabolism and nutrition disorders:
Frequency not known: dehydration

Psychiatric disorders:
Common: agitation, confusion, anxiety
Uncommon: insomnia, depression
Very rare: hallucinations
Frequency not known: aggression, restlessness

Skin and subcutaneous disorders:
Common: hyperhydrosis
Rare: rash, pruritis

Disseminated cutaneous hypersensitivity reactions have also been observed (frequency not known).

Additional adverse drug reactions which have been reported with Exelon Patch:
Common: urinary incontinence
Uncommon: cerebrovascular accident, delirium, psychomotor hyperactivity.
Rarely reported: erythema, urticaria, blister, dermatitis allergic.

DOSEAGE AND ADMINISTRATION

The dosage of Exelon shown to be effective in controlled clinical trials is 6-12 mg/day, given as twice a day dosing (daily doses of 3 to 6 mg twice daily). There is evidence from the clinical trials that doses at the higher end of this range may be more beneficial. Patients should be individually titrated to establish the appropriate dosage of Exelon.

Exelon should be administered twice daily with morning and evening meals. The capsules should be swallowed whole. The prescribed amount of Exelon Oral solution should be withdrawn from the container using the oral dosing syringe. Exelon Oral solution may be swallowed directly from the syringe. Alternatively, the solution may be added to a small glass of water, cold orange or apple juice or Coca-Cola. Exelon Oral solution and Exelon capsules may be interchanged at equal doses.

Starting dose: The recommended starting dose is 1.5 mg twice daily.

Dose titration: If the starting dose is well tolerated after a minimum of two weeks of treatment, the dose may be increased to 3 mg twice daily. Subsequent increases to 4.5 mg and then 6 mg twice daily should also be based on tolerability of the current dose and may be considered after a minimum of two weeks treatment at that dose level.

If adverse effects (e.g. nausea, vomiting, abdominal pain, loss of appetite or weight decrease) are observed during treatment, these may respond to omission of one or more doses. If adverse effects persist, the daily dose should be reduced to the previous well-tolerated dose.

Maintenance dose: 1.5 to 6 mg twice daily. To achieve maximum therapeutic benefit, patients should be maintained on their highest well-tolerated dose.

Maximum recommended dose: 6 mg twice daily.
Re-initiation of therapy:

The incidence and severity of adverse events are generally increased with higher doses.

If treatment is interrupted for longer than several days, treatment should be re-initiated with the lowest daily dose and titrated as described above (see "PRECAUTIONS").

Use in patients with renal or hepatic impairment:

No dose adjustment is necessary in patients with renal or hepatic impairment. However, due to increased exposure in renal impairment and mild to moderate hepatic impairment, dosing recommendations to titrate according to individual tolerability should be closely followed. (see "PHARMACOLOGY - Pharmacokinetics in renal impairment; Pharmacokinetics in hepatic impairment").

OVERDOSAGE

Symptoms:

Most cases of accidental overdosage have not been associated with any clinical signs or symptoms and almost all of the patients concerned continued Exelon treatment. Where symptoms have occurred, they have included severe nausea, vomiting, diarrhoea, hypertension, hallucinations, salivation, sweating, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Atypical responses in blood pressure and heart rate have been reported with other drugs that increase cholinergic activity when co-administered with quarternary anticholinergics such as glycopyrrolate. Due to the known vagotonic effect of cholinesterase inhibitors on heart rate, bradycardia and/or syncope may also occur. Ingestion of 46 mg occurred in one case but, following conservative management, the patient fully recovered within 24 hours.

Treatment:

As rivastigmine has a plasma half-life of about 1 hour and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that, in cases of asymptomatic overdoses, no further dose of Exelon should be administered for the next 24 hours. In overdose accompanied by severe nausea and vomiting, the use of antiemetics should be considered. Symptomatic treatment for other adverse events should be given as necessary.

Due to the short half-life of Exelon, dialysis (haemodialysis, peritoneal dialysis or haemofiltration) would not be clinically indicated in the event of an overdose.

In massive overdoses, atropine can be used. An initial intravenous dose of 0.03 mg/kg atropine sulphate is recommended, with subsequent doses based upon clinical response. Use of hyoscine as an antidote is not recommended.

Contact the Poisons Information Centre on 13 11 26 for advice on management.
PRESENTATION AND STORAGE CONDITIONS

Exelon capsules contain 1.5, 3.0, 4.5 or 6.0 mg rivastigmine as the hydrogen tartrate salt; in blister packs of 14, 28, 56 and 112 capsules.

**Storage:** Store below 25°C. Keep out of the reach of children.

Exelon Oral solution is available in a 120 or 50 mL glass bottle and contains rivastigmine hydrogen tartrate corresponding to rivastigmine base 2 mg/mL. The oral solution is packaged with an oral dosing syringe in a plastic tube container.

**Storage:** Store below 30°C. Do not freeze. Keep out of the reach of children.

Not all strengths and pack sizes may be marketed.

NAME AND ADDRESS OF THE SPONSOR

NOVARTIS Pharmaceuticals Australia Pty Limited
ABN 18 004 244 160
54 Waterloo Road
NORTH RYDE NSW 2113

® = Registered Trademark

POISON SCHEDULE OF THE MEDICINE

Prescription Medicine (Schedule 4).

DATE OF FIRST INCLUSION IN THE ARTG

06 June 2000

DATE OF MOST RECENT AMENDMENT

Date of most recent amendment: 30 August 2012